Which has better earnings and valuation, INGN or CBLL?

Inogen has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.49 -$22.75M -$0.91 N/A CeriBell $95.07M 7.12 -$53.41M -$1.63 N/A

Is INGN or CBLL more profitable?

Inogen has a net margin of -7.08% compared to CeriBell's net margin of -63.51%. Inogen's return on equity of -12.90% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -7.08% -12.90% -8.27% CeriBell -63.51% -38.19% -30.92%

Which has higher valuation and earnings, INGN or SIBN?

SiBone has lower revenue, but higher earnings than Inogen. SiBone is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.49 -$22.75M -$0.91 N/A SiBone $206.22M 3.27 -$18.90M -$0.39 N/A

Is INGN or SIBN more profitable?

Inogen has a net margin of -7.08% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -7.08% -12.90% -8.27% SiBone -8.10% -9.56% -7.06%

Which has preferable earnings & valuation, SGP or INGN?

Spyglass Pharma has higher earnings, but lower revenue than Inogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A N/A N/A N/A Inogen $348.67M 0.49 -$22.75M -$0.91 N/A

Which has higher earnings and valuation, BBNX or INGN?

Inogen has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $110.24M 5.67 -$73.20M -$1.51 N/A Inogen $348.67M 0.49 -$22.75M -$0.91 N/A

Is BBNX or INGN more profitable?

Inogen has a net margin of -7.08% compared to Beta Bionics' net margin of -60.27%. Inogen's return on equity of -12.90% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -60.27% -23.00% -20.55% Inogen -7.08% -12.90% -8.27%

Inogen (INGN) Competitors

$6.38 -0.21 (-3.11%)

As of 01:10 PM Eastern

Compare

INGN vs. CBLL, SIBN, SGP, BBNX, and TCMD

Should you buy Inogen stock or one of its competitors? MarketBeat compares Inogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inogen include CeriBell (CBLL), SiBone (SIBN), Spyglass Pharma (SGP), Beta Bionics (BBNX), and Tactile Systems Technology (TCMD). These companies are all part of the "medical equipment" industry.

How does Inogen compare to CeriBell?

Inogen (NASDAQ:INGN) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

89.9% of Inogen shares are held by institutional investors. 2.5% of Inogen shares are held by company insiders. Comparatively, 20.1% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, CeriBell had 5 more articles in the media than Inogen. MarketBeat recorded 6 mentions for CeriBell and 1 mentions for Inogen. Inogen's average media sentiment score of 1.24 beat CeriBell's score of 0.37 indicating that Inogen is being referred to more favorably in the media.

Company	Overall Sentiment
Inogen	Positive
CeriBell	Neutral

Inogen has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.49	-$22.75M	-$0.91	N/A
CeriBell	$95.07M	7.12	-$53.41M	-$1.63	N/A

Inogen has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Inogen has a net margin of -7.08% compared to CeriBell's net margin of -63.51%. Inogen's return on equity of -12.90% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-7.08%	-12.90%	-8.27%
CeriBell	-63.51%	-38.19%	-30.92%

Inogen presently has a consensus target price of $14.00, suggesting a potential upside of 120.13%. CeriBell has a consensus target price of $22.20, suggesting a potential upside of 24.40%. Given Inogen's higher probable upside, equities analysts clearly believe Inogen is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Inogen beats CeriBell on 11 of the 16 factors compared between the two stocks.

How does Inogen compare to SiBone?

Inogen (NASDAQ:INGN) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

SiBone has lower revenue, but higher earnings than Inogen. SiBone is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.49	-$22.75M	-$0.91	N/A
SiBone	$206.22M	3.27	-$18.90M	-$0.39	N/A

Inogen presently has a consensus target price of $14.00, indicating a potential upside of 120.13%. SiBone has a consensus target price of $23.00, indicating a potential upside of 51.12%. Given Inogen's higher probable upside, analysts clearly believe Inogen is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, SiBone had 4 more articles in the media than Inogen. MarketBeat recorded 5 mentions for SiBone and 1 mentions for Inogen. Inogen's average media sentiment score of 1.24 beat SiBone's score of 0.45 indicating that Inogen is being referred to more favorably in the media.

Company	Overall Sentiment
Inogen	Positive
SiBone	Neutral

89.9% of Inogen shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 2.5% of Inogen shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Inogen has a net margin of -7.08% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-7.08%	-12.90%	-8.27%
SiBone	-8.10%	-9.56%	-7.06%

Inogen has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, SiBone has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Summary

SiBone beats Inogen on 10 of the 17 factors compared between the two stocks.

How does Inogen compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Inogen (NASDAQ:INGN) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

In the previous week, Spyglass Pharma and Spyglass Pharma both had 1 articles in the media. Spyglass Pharma's average media sentiment score of 1.87 beat Inogen's score of 1.24 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Spyglass Pharma	Very Positive
Inogen	Positive

89.9% of Inogen shares are held by institutional investors. 2.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Spyglass Pharma has higher earnings, but lower revenue than Inogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
Inogen	$348.67M	0.49	-$22.75M	-$0.91	N/A

Spyglass Pharma presently has a consensus target price of $45.00, indicating a potential upside of 147.52%. Inogen has a consensus target price of $14.00, indicating a potential upside of 120.13%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Inogen	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Spyglass Pharma has a net margin of 0.00% compared to Inogen's net margin of -7.08%. Spyglass Pharma's return on equity of 0.00% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Inogen	-7.08%	-12.90%	-8.27%

Summary

Spyglass Pharma beats Inogen on 7 of the 11 factors compared between the two stocks.

How does Inogen compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

89.9% of Inogen shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 2.5% of Inogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Beta Bionics has a beta of 3.4, meaning that its stock price is 240% more volatile than the broader market. Comparatively, Inogen has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Inogen has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$110.24M	5.67	-$73.20M	-$1.51	N/A
Inogen	$348.67M	0.49	-$22.75M	-$0.91	N/A

Beta Bionics presently has a consensus price target of $19.70, indicating a potential upside of 40.50%. Inogen has a consensus price target of $14.00, indicating a potential upside of 120.13%. Given Inogen's stronger consensus rating and higher possible upside, analysts clearly believe Inogen is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Inogen	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Inogen has a net margin of -7.08% compared to Beta Bionics' net margin of -60.27%. Inogen's return on equity of -12.90% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Inogen	-7.08%	-12.90%	-8.27%

In the previous week, Beta Bionics had 8 more articles in the media than Inogen. MarketBeat recorded 9 mentions for Beta Bionics and 1 mentions for Inogen. Inogen's average media sentiment score of 1.24 beat Beta Bionics' score of 0.07 indicating that Inogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Beta Bionics	Neutral
Inogen	Positive

Summary

Inogen beats Beta Bionics on 11 of the 16 factors compared between the two stocks.

How does Inogen compare to Tactile Systems Technology?

Tactile Systems Technology (NASDAQ:TCMD) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Tactile Systems Technology has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Inogen has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

In the previous week, Tactile Systems Technology had 1 more articles in the media than Inogen. MarketBeat recorded 2 mentions for Tactile Systems Technology and 1 mentions for Inogen. Inogen's average media sentiment score of 1.24 beat Tactile Systems Technology's score of 0.62 indicating that Inogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Tactile Systems Technology	Positive
Inogen	Positive

Tactile Systems Technology has a net margin of 5.91% compared to Inogen's net margin of -7.08%. Tactile Systems Technology's return on equity of 9.70% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tactile Systems Technology	5.91%	9.70%	7.53%
Inogen	-7.08%	-12.90%	-8.27%

Tactile Systems Technology presently has a consensus price target of $38.60, indicating a potential upside of 49.09%. Inogen has a consensus price target of $14.00, indicating a potential upside of 120.13%. Given Inogen's higher probable upside, analysts clearly believe Inogen is more favorable than Tactile Systems Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Inogen	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

83.4% of Tactile Systems Technology shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 2.1% of Tactile Systems Technology shares are owned by insiders. Comparatively, 2.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tactile Systems Technology has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tactile Systems Technology	$343.52M	1.70	$19.09M	$0.88	29.42
Inogen	$348.67M	0.49	-$22.75M	-$0.91	N/A

Summary

Tactile Systems Technology beats Inogen on 10 of the 16 factors compared between the two stocks.

Get Inogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INGN vs. The Competition

Export

Metric	Inogen	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$172.77M	$7.02B	$6.49B	$11.73B
Dividend Yield	N/A	1.20%	2.67%	5.61%
P/E Ratio	-7.01	47.58	24.65	23.79
Price / Sales	0.49	45.78	476.12	85.79
Price / Cash	N/A	25.48	43.05	54.72
Price / Book	0.90	6.88	10.45	6.74
Net Income	-$22.75M	$159.22M	$3.56B	$337.26M
7 Day Performance	0.79%	-5.44%	-2.43%	-1.85%
1 Month Performance	-3.93%	3.90%	0.23%	0.94%
1 Year Performance	-1.40%	-2.74%	21.35%	24.84%

Inogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INGN Inogen	3.5073 of 5 stars	$6.39 -3.1%	$14.00 +119.3%	-0.5%	$172.85M	$348.67M	N/A	1,030
CBLL CeriBell	2.6255 of 5 stars	$18.14 -0.6%	$22.20 +22.4%	+3.7%	$692.45M	$89.06M	N/A	N/A	News Coverage Insider Trade
SIBN SiBone	2.2796 of 5 stars	$14.97 -1.0%	$23.00 +53.6%	-19.5%	$670.56M	$200.93M	N/A	350
SGP Spyglass Pharma	N/A	$18.74 -0.2%	$45.00 +140.1%	N/A	$626.53M	N/A	N/A	65
BBNX Beta Bionics	3.2753 of 5 stars	$13.87 -0.1%	$19.70 +42.0%	-28.8%	$618.96M	$100.25M	N/A	294	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INGN) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inogen (INGN) Competitors